New York, NY (PRWEB) August 22, 2012
The Crohn’s & Colitis Foundation of America (CCFA) and Imedex are pleased to announce abstract submission 2012 Advances in Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference in Hollywood, Florida on December 13-15, 2012 is now open.
One of the goals of the conference is to present the best new scientific research in IBD and advance knowledge on the state of the science. Health care professionals with an interest in the treatment of pediatric and adult patients with inflammatory bowel diseases are invited to share their research initiatives with the healthcare community by submitting an abstract. Accepted abstracts will be published in the journal Inflammatory Bowel Diseases and scheduled for oral or poster presentation.
In 2011 a record number of 311 abstracts were accepted for presentation, and the first North American presentation of data from the Immunochip Project of the International IBD Genetics Consortium (IIBDGC) was discussed during an oral abstract session. This important project examined the shared risk genes between inflammatory bowel disease and other immune-mediated disorders in order to further identify genetic risk loci for IBD.
“Last year’s event was amazing, with so many great submissions from all over our scientific community. 2012 is shaping up to be even better,” said conference co-chair Dr. Stephen B. Hanauer. “We have a larger space to accommodate more posters, more attendees, and more cutting edge research this year. This is an incredible way to participate in one of inflammatory bowel disease’s most prominent events.”
Abstracts are subject to acceptance by the Scientific Committee. Abstracts should be submitted at http://www.advancesinibd.com by September 9, 2012. Accepted abstracts will be presented at the conference on December 13-15, 2012 in Hollywood, Florida.
Additionally, a limited number of travel grants are being offered to gastrointestinal fellows, nurses and nurse practitioners to attend the 2012 Advances in Inflammatory Bowel Diseases Crohn’s & Colitis Foundation’s Clinical & Research Conference. The travel grant includes travel, hotel accommodations and conference registration. Details can be found at http://www.advancesinibd.com.
This year commemorates the 11th anniversary of what has become the “can’t miss” event for healthcare professionals and researchers who study and manage patients with inflammatory bowel diseases. Co-chaired by Richard P. MacDermott, MD, MACG and Stephen B. Hanauer, MD, FACG, the outstanding faculty is comprised of over 55 expert specialists who will lead the sessions and interact with conference attendees. Workshops (The Future of IBD and The Basics of IBD) will be featured alongside the expanded three-track format for clinicians and researchers. The conference also continues to offer expanded sessions for nurses and pediatric gastroenterologists. All tracks will be comprised of the foremost bench to bedside leaders from across the country.
About the Crohn's & Colitis Foundation
The Crohn's & Colitis Foundation of America (CCFA) is the largest voluntary non-profit health organization dedicated to finding cures for Inflammatory Bowel Diseases (IBD). CCFA’s mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults who suffer from these diseases. The Foundation works to fulfill its mission by funding research, providing educational resources for patients and their families, medical professionals, and the public, and furnishing supportive services for those afflicted with IBD. For more information, visit http://www.ccfa.org, call 888-694-8872, like us on Facebook, or follow us on Twitter.
Imedex is an industry leader in providing accredited, independent continuing medical education to health care professionals. We develop high quality scientific programming that translates the latest research into clinically relevant information. The activities have exceptional organization and outstanding educational value, with a proven sustained impact on disease management.
Our programs focus on improving patient care around the world. With over 50,000 e-learning experiences annually and more than 97,000 live meeting attendees since 2001, Imedex truly educates the global healthcare community. At Imedex, education is the best medicine.®